NCT03539822View on ClinicalTrials.gov

Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Gastric CancerEsophageal AdenocarcinomaHepatocellular CarcinomaColorectal Cancer
Interventions
DRUG

Cabozantinib

by mouth

DRUG

Durvalumab

infusion

DRUG

Tremelimumab

infusion

Trial Locations (2)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

66205

TERMINATED

University of Kansas Cancer Center, Westwood

Sponsors

Collaborators (2)

AstraZeneca
Exelixis
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Exelixis

INDUSTRY

lead

Anwaar Saeed

OTHER